Merus BV (MRUS)

Merus BV (MRUS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Dec 29, 2025: market cap $6.8B; returns 1 week -7.2%, 1 year +113.9%.

Merus N.V. is a clinical-stage oncology biotechnology company headquartered in Utrecht, Netherlands, focused on developing innovative, full-length human multispecific antibodies, including bispecific (Biclonics®) and trispecific (Triclonics®) antibodies, and antibody-drug conjugates (ADClonics®).

MRUS financial model: income statement, cash flow and balance sheet